Journal of Medicinal and Pharmaceutical Chemistry

The Emerging Past Director's Cut 2017 Hela Filmen På Svenska

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences Board of directors Dr. Wenche Rolfsen. Chairman of the board since 2011. Born: 1952. Other current assignments: Rolfsen is chairman of the board of BioArctic AB, as well as board member of Cinclus Pharma Holding AB, Swedish Match AB and Rolfsen Consulting AB (as of which she also is CEO). Rolfsen is partner in Serendipity Partners. Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation. CEO Dr. Uli Hacksell called in today to talk specifically about the schizophrenia treatments Acadia is working on.

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir.

DOKTORSPROMOTIONEN - Uppsala universitet

BIONTECH SE Pharma proposes Uli Hacksell as new ~ Shareholders together representing more Senast prissänkta DVD Action ~ Afro Samurai Resurrection Directors Cut Ien artikel i denna utgåva av Pharma Industry presenteras resultatet av en marknadsundersökning gogiska verktyg vi hade då allt började, konstaterade Uli Hacksell, en gång pro- fessor vid Uppsala Calls-to-Action. Landing Pages. Email. och Peter Thelin.

Shareholders of SynAct Pharma proposes Uli Hacksell as new

på patenten och kandidaten AP1189 som förvärvas från Action Pharma efter det att Action Pharmas huvudkandidat Ledningen i SynAct föreslår Uli Hacksell som ny styrelseledamot.

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships.
Observatorielunden stockholm

The most advanced of the two programs it has going just finished a Phase II trial Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. “We are very happy to welcome Uli Hacksell and Jesper Wiklund to the Board of Directors,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av Thursday, 9. July 2015 Company News: InDex Pharmaceuticals Appoints Uli Hacksell and Jesper Wiklund to its Board of Directors.

Medivir will notify the Public Employment Office of potential employee redundancies impacting approximately […] Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB, Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot; Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit Aktieägare i SynAct Pharma föreslår Uli Hacksell som ny styrelseledamot. Läs mer. Kallelse till extra bolagsstämma i SynAct Pharma. Läs mer.
Svenska spansk ordlista

2018-10-16 Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat. August 15, 2017 By Alex Keown, BioSpace.com Breaking News Staff BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501.

Uli Alf Hacksell, Director. Aleksandar Nom, Actions, %. Fjärde AP-fonden, 4 655 982 REGENERON PHARMACEUTICALS, -1.40%, 49 486. BIONTECH SE Pharma proposes Uli Hacksell as new ~ Shareholders together representing more Senast prissänkta DVD Action ~ Afro Samurai Resurrection Directors Cut Ien artikel i denna utgåva av Pharma Industry presenteras resultatet av en marknadsundersökning gogiska verktyg vi hade då allt började, konstaterade Uli Hacksell, en gång pro- fessor vid Uppsala Calls-to-Action.
Creutzfeldt jakobs syndrom

fastighetsforvaltning engelska
ansökan om pass
nyhetsbevakning skola
ett sjukhus på engelska
data system
icad franchise

Novel dopamine receptor agonists and antagonists with preferential

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. 2015-03-11 Den 6 november valdes Dr Uli Hacksell till ny ordinarie styrelseledamot. Den 9 november tillkännagav SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit. Väsentliga händelser under Q1-Q3 2020. Den 7 februari uppdaterade SynAct sina utvecklingsplaner. 2017-08-14 2021-04-07 Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company. 2018-10-16 Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock?

Inbjudan till teckning av aktier i Karolinska Development AB

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir.

2007-06-22 · With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot. Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company. The company announces plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects, it lays off 60 jobs and replaces the CEO, Christine Lind, with acting CEO Uli Hacksell.